Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus


      • Type 2 Diabetes Mellitus (T2DM) is a current global threat.
      • Sodium-glucose co-transporter 2 inhibitor is a new approach for T2DM management.
      • Combined therapy of SGLT2 inhibitor and metformin is more effective.



      Type 2 Diabetes Mellitus (T2DM) is a chronic disorder and its treatment with only metformin often does not provide optimum glycemic control. Addition of sodium glucose cotransporter 2 inhibitor (SGLT2) will improve the glycemic control in patients on metformin alone. In this study, an attempt is made to investigate the combined therapy of SGLT-2 with metformin in managing T2DM in terms of lowering HbA1c and body weight and monotherapy using metformin alone in HbA1c and body weight reduction.


      To compare the clinical effectiveness of combined therapy using SGLT2 inhibitor and metformin with monotherapy using metformin alone in HbA1c and body weight reduction.


      A systematic review of the randomized controlled trials has been carried out and Cochrane risk of bias tool was used for the quality assessment. Patient, Intervention, Comparison and Outcomes (PICO) technique is used to select the relevant articles to meet the objective.


      The studies used in this article are multicenter, double-blinded randomized controlled trials on SGLT2 inhibitors with methformin, there were a total of 3897 participants, with a range of 182 to 1186 individual study size were included. Studies showed that combined therapy were more effective in HbA1c and body weight reduction as compared to monotherapy.


      The combined therapy of SGLT2 inhibitor along with metformin is more effective in HbA1c reduction and weight reduction as compared to monotherapy using metformin alone. Among the three SGLT2 inhibitors such as dapagliflozin canagliflozin and empagliflozin do not differ much in the efficiency of weight reduction. However, Empagliflozin 25 mg is effective in HbA1c reduction.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Diabetes mellitus (Internet). WHO. (cited 2017 Mar 1). Available from: <>.

      2. Non-communicable disease, risk factors and other health problems. National health and morbidity survey 2015. Ministry of Health Malaysia 2015;2:14–6.

      3. Mortality among type 2 diabetic in-patient in a nigerian tertiary hospital. AJDM. November 2016;24(2):14–20.

        • Inzucchi S.E.
        • Zinman B.
        • Wanner C.
        • Ferrari R.
        • Fitchett D.
        • Hantel S.
        • et al.
        SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
        Diab Vasc Dis Res. 2015 Mar; 12: 90-100
        • Tan X.
        • Hu J.
        Combination therapy for type 2 diabetes: dapagliflozin plus metformin.
        Expert Opin Pharmacother. 2016; 17: 117-126
        • Bailey C.J.
        • Morales Villegas E.C.
        • Woo V.
        • Tang W.
        • Ptaszynska A.
        • List J.F.
        Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
        Diabet Med J Br Diabet Assoc. 2015 Apr; 32: 531-541
        • Cuypers J.
        • Mathieu C.
        • Benhalima K.
        Sglt2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of Sglt2-Inhibitors in clinical practice.
        Acta Clin Belg. 2013 Aug 1; 68: 287-293
        • Schumm-Draeger P.-M.
        • Burgess L.
        • Korányi L.
        • Hruba V.
        • Hamer-Maansson J.E.
        • de Bruin T.W.A.
        Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
        Diabetes Obes Metab. 2015 Jan; 17: 42-51
        • Rosenstock J.
        • Aggarwal N.
        • Polidori D.
        • Zhao Y.
        • Arbit D.
        • Usiskin K.
        • et al.
        Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
        Diabetes Care. 2012 Jun; 35: 1232-1238
        • Rosenstock J.
        • Seman L.J.
        • Jelaska A.
        • Hantel S.
        • Pinnetti S.
        • Hach T.
        • et al.
        Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
        Diabetes Obes Metab. 2013 Dec; 15: 1154-1160
        • Bolinder J.
        • Ljunggren Ö.
        • Johansson L.
        • Wilding J.
        • Langkilde A.M.
        • Sjöström C.D.
        • et al.
        Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
        Diabetes Obes Metab. 2014 Feb; 16: 159-169
        • Merker L.
        • Häring H.-U.
        • Christiansen A.V.
        • Roux F.
        • Salsali A.
        • Kim G.
        • et al.
        Empagliflozin as add-on to metformin in people with type 2 diabetes.
        Diabet Med J Br Diabet Assoc. 2015 Dec; 32: 1555-1567
        • Rosenstock J.
        • Chuck L.
        • González-Ortiz M.
        • Merton K.
        • Craig J.
        • Capuano G.
        • et al.
        Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve type 2 diabetes.
        Diabetes Care. 2016 Mar; 39: 353-362
        • Zou Honghong.
        • Zhou Baoqin.
        Gaosi Xu SGLT2 inhibitors:a novel choice for the combination therapy in diabetic kidney disease.
        Cardiovasc Diabetrol. 2017; 16: 65
        • Elisaf M.
        • Tzavela E.
        • Karanatsis N.
        • Tsimichodimos V.
        Antidiabetic drugs and the kidney.
        Curr Pharm Des. 2017; 3222